Comparison of effects of 5 and 10 mg oral desloratadine and levocetirizine on histamine-induced wheal and flare response in healthy volunteers

2013 ◽  
Vol 24 (6) ◽  
pp. 473-476 ◽  
Author(s):  
Songül Bulca ◽  
Dilek Bayramgürler ◽  
Evren Odyakmaz Demirsoy ◽  
Melike Yavuz ◽  
Aysun Şikar Aktürk ◽  
...  
Keyword(s):  
Healthy Volunteers ◽  
Flare Response ◽  
Wheal And Flare

Comparative efficacy of bilastine, desloratadine and rupatadine in the suppression of wheal and flare response induced by intradermal histamine in healthy volunteers

2016 ◽  
Vol 33 (1) ◽  
pp. 129-136 ◽  
Author(s):  
Rosa Antonijoan ◽  
Jimena Coimbra ◽  
Consuelo García-Gea ◽  
Montserrat Puntes ◽  
Ignasi Gich ◽  
...  
Keyword(s):  
Healthy Volunteers ◽  
Comparative Efficacy ◽  
Flare Response ◽  
Wheal And Flare

An Evaluation of the Antihistamine Activity of Acrivastine and Its Onset in Human Skin

1992 ◽  
Vol 20 (2) ◽  
pp. 106-111 ◽  
Author(s):  
V K Manna ◽  
P Marks ◽  
J R Gibson
Keyword(s):  
Crossover Study ◽  
Healthy Volunteers ◽  
Human Skin ◽  
Treatment Plan ◽  
Onset Of Action ◽  
Double Blind ◽  
Time Points ◽  
Antihistamine Activity ◽  
Flare Response ◽  
Histamine Challenge

In a double-blind, two-period crossover study, 24 healthy volunteers were evaluated to establish the time of onset of action of activity of acrivastine in suppressing the weal and flare response to intradermally injected histamine. Volunteers received single doses of 8 mg acrivastine and placebo according to a fully randomized, balanced treatment plan. Acrivastine significantly ( P < 0.002) reduced the flare response induced by 0.4 μg histamine challenge 15 min after oral acrivastine dosing when compared with placebo. A significant ( P < 0.001) reduction of the weal response was noted at 25 min, although trends in this direction were already present at earlier time points. Dans d'une étude croisée à deux phase, réalisée en double aveugle et ayant porté sur 24 volontaires sains, on a tenté d'établir le moment du début de l'action de l'acrivastine dans la suppression de la réponse inflammatoire consécutive à l'injection intradermique d'histamine. Les volontaires ont reçu des doses uniques de 8 mg d'acrivastine et de placebo, selon un plan de traitement entièrement randomisé et équilibré. L'acrivastine a réduit significativement ( P < 0,002) la réponse de rubéfaction induite par 0,4 μg d'histamine 15 minutes après l'administration orale d'acrivastine, par rapport au placebo. Une réduction significative ( P < 0,001) de la réponse d'enflure a été notée à 25 minutes, bien qu'une tendance en ce sens ait déjà été observée à un stade plus précoce.

Pain, Tenderness, Wheal and Flare Induced by Substance-P, Bradykinin and 5-Hydroxytryptamine in Humans

Cephalalgia ◽  
1991 ◽  
Vol 11 (4) ◽  
pp. 175-182 ◽  
Author(s):  
Kai Jensen ◽  
Christian Tuxen ◽  
Ulrik Pedersen-Bjergaard ◽  
Inger Jansen
Keyword(s):  
Substance P ◽  
Healthy Volunteers ◽  
Human Skin ◽  
Pain Threshold ◽  
Pressure Pain Threshold ◽  
Temporal Muscle ◽  
Pressure Pain ◽  
Forearm Skin ◽  
Flare Reaction ◽  
Wheal And Flare

The algesic effect of substance-P with and without the addition of bradykinin or 5-hydroxytryptamine was studied in 13 healthy volunteers. Test substances dissolved in saline were injected into the temporal muscle and the forearm skin and the effects compared with those of saline. In the temporal muscle, none of the test substances induced more pain than saline, but substance-P with bradykinin lowered the pressure pain threshold by 18% ( p < 0.02). All test substances induced pain, wheal and flare in the forearm skin. Substance-P induced a more pronounced flare reaction than bradykinin, whereas the latter induced more pain than substance-P. This dissociation between pain and flare may indicate that C-fibres in the human skin represent more than one type of nociceptor.

Sign in / Sign up

Export Citation Format

Share Document